Understanding the mechanisms of resistance to cisplatin and PARP inhibitors is paramount for identification of biomarkers to predict the tumor response to therapy, as well as for designing therapeutic approaches to target this chemoresistance. This evidence concerns the gene PARP1 and neoplasm.